"The one-year OLYMPIA data show excellent outcomes with the TAXUS Liberte stent system across a large patient population with a broad range of lesion complexity, including diabetics who have typically demonstrated increased event rates," said Jeff Goodman, President of Boston Scientific International. "Our second-generation stent platform - TAXUS Liberte - offers exceptional deliverability and is the only current drug-eluting stent geometry designed specifically for drug elution. The strong clinical results, excellent performance in diabetics and solid physician preference have allowed TAXUS Liberte to take a clear leadership role in European and Intercontinental markets."
The global, prospective OLYMPIA registry is the world's largest DES registry and plans to enroll up to 26,000 patients from more than 400 centers worldwide. OLYMPIA is designed to analyze real-world clinical outcomes data for Boston Scientific's second-generation TAXUS Liberte paclitaxel-eluting stent system in the treatment of patients with coronary artery disease.
The OLYMPIA European and Intercontinental launch phases consisted of diverse and high-risk patient populations, reflecting complex usage patterns in "real-world" clinical practices. A majority of patients exhibited complex lesions or clinical characteristics, including, multi-vessel disease (57.7 percent), prior myocardial infarction (MI) (37.3 percent), acute MI (17.8 percent), multiple stents (32.9 percent), type B2/C lesions (56.6 percent) and diabetes (33.4 percent). Of the first 7,124 patients enrolled, 92.5 percent (6,593 patients) were available for evaluation at one year.
Patients with a single vessel treated with only one TAXUS Liberte stent
were considered simple use patients and comprised 27.6 percent of the
total. Complex use p
|SOURCE Boston Scientific Corporation|
Copyright©2007 PR Newswire.
All rights reserved